Home Uncategorized Alcon Releases 2022 Annual General Meeting Agenda

Alcon Releases 2022 Annual General Meeting Agenda

0

GENEVA–(BUSINESS WIRE)–Regulatory news:

Alcon (SIX/NYSE:ALC), the global eye care leader, will hold its Annual General Meeting (AGM) on April 27, 2022.

Due to the ongoing tense situation due to the COVID-19 pandemic, and as a precautionary and prudent measure, the Board of Directors of Alcon has decided to hold the general meeting behind closed doors without the personal presence of the shareholders. , as permitted by the Swiss Ordinance and for the safety of Alcon shareholders and associates. Alcon asks its shareholders to exercise their rights at the AGM exclusively by sending their voting instructions to the independent proxy identified in the voting materials.

The Alcon Board of Directors proposes that the AGM elect Raquel C. Bono, MD as a new Board member. A board-certified trauma surgeon and retired vice admiral of the US Navy Medical Corps, Dr. Bono was the first female three-star medical admiral in US Navy history, as well as the first female American- Asian promoted to Vice-Admiral. Dr. Bono has served as Chief Healthcare Officer at Viking, Inc. since November 2020 and Principal at RCB Consulting since October 2019. She brings more than 25 years of experience in healthcare leadership roles to Alcon’s Board of Directors. health care and extensive experience in the field of health care. industry and the areas of government relations and regulatory/public policy.

The invitation to the AGM, including explanatory information on the individual agenda items, was published in the Swiss Gazette of Commerce on March 24, 2022 and is available online at https:// investor.alcon.com/news-and-events/events-and-presentations/event-details/2022/2022-Annual-General-Meeting/default.aspx.

Alcon 2022 AGM Agenda

1.

Approval of Alcon Inc. Operational and Financial Review, Alcon Inc. Annual Financial Statements and Consolidated Financial Statements for 2021

2.

Discharge to the members of the Board of Directors and the members of the Executive Committee

3.

Appropriation of earnings and declaration of dividend according to the balance sheet of Alcon Inc. as of December 31, 2021

▪ If approved by shareholders, a dividend of CHF 0.20 in cash per share will be payable with a record date scheduled for May 2, 2022 and a Swiss payment date scheduled for May 5, 2022 or around this date. a tax of 35% will be deducted from the gross amount of the dividend.

4.

Votes on the remuneration of the Board of Directors and the Executive Committee

4.1

Advisory vote on the 2021 compensation report

4.2

Binding vote on the maximum aggregate amount of the compensation of the Board of Directors for the next term, i.e. from the General Meeting 2022 to the General Meeting 2023

4.3

Binding vote on the maximum aggregate amount of the Executive Committee’s remuneration for the following financial year, i.e. 2023

5.

Re-election and election of the president and members of the board of directors

5.1

Re-election of F. Michael Ball (as member and president)

5.2

Re-election of Lynn D. Bleil (as a member)

5.3

Re-election of Arthur Cummings (as a member)

5.4

Re-election of David J. Endicott (as a member)

5.5

Re-election of Thomas Glanzmann (as a member)

5.6

Re-election of D. Keith Grossman (as a member)

5.7

Re-election of Scott Maw (as a member)

5.8

Re-election of Karen May (as a member)

5.9

Re-election of Ines Pöschel (as a member)

5.10

Re-election of Dieter Spälti (as a member)

5.11

Election of Raquel C. Bono (as a member)

6.

Re-election and election of members of the Compensation Committee

6.1

Re-election of Thomas Glanzmann

6.2

Re-election of Karen May

6.3

Re-election of Ines Pöschel

6.4

Election of Scott Maw

7.

Re-election of the independent representative

8.

Re-election of the auditors

Caution Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as: “anticipate”, “intend “, “commitment”, “expect”, “maintain”, “plan”, “objective”, “seek”, “target”, “assume”, “believe”, “project”, “estimate”, “expect to”, “strategy”, “future”, “probable”, “may”, “should”, “will” and similar references to future periods. An example of a forward-looking statement includes, but is not limited to, statements made by Alcon regarding the payment of a dividend.

Forward-looking statements are neither historical facts nor guarantees of future performance. Instead, they are based solely on our current beliefs, expectations and assumptions about the future of our business, our future plans and strategies and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may differ materially from those anticipated. Accordingly, you should not rely on any such forward-looking statements.

The forward-looking statements contained in this press release speak only as of the date they are made, and we undertake no obligation to update any forward-looking statements as a result of new information, future events or otherwise. .

About Alcon

Alcon helps people see brilliantly. As a global leader in eye care with a heritage of over 75 years, we offer the broadest portfolio of products to improve sight and improve people’s lives. Our surgical and vision care products touch the lives of more than 260 million people in more than 140 countries each year living with conditions such as cataracts, glaucoma, retinal disease and refractive errors. Our more than 24,000 associates improve quality of life through innovative products, partnerships with eye care professionals and programs that improve access to quality eye care. For more information, visit www.alcon.com.

Join us on

Facebook

LinkedIn